The American Journal of Managed Care

Latest NCCN Guidelines on the Standard of Care for Patients With AML

Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper ...

NCCN Guidelines Navigator for Breast Cancer Genetic Testing and Treatment Debuts During Breast Cancer Awareness Month

Today, the National Comprehensive Cancer Network® (NCCN®)—a nonprofit responsible for globally utilized guidelines for cancer ...
The American Journal of Managed Care

Advancing Care and Future Impact of NCCN Updates in ROS1+ NSCLC

A key barrier in advancing care for ROS1-positive non-small cell lung cancer (NSCLC) is the rarity of the condition, affecting only about 1.5% to 2% of patients. While this still represents a notable ...
EurekAlert!

Cancer genetic risk assessment guidelines expand to meet growing understanding of hereditary risk

National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting edge research into genetic/familial high-risk ...

Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best stocks to buy under $20. On September 19, Syndax Pharmaceuticals announced a major milestone: the National Comprehensive Cancer ...
Business Wire

Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...
Business Wire

NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...
Nasdaq

Invivyd, Inc. Announces Inclusion of PEMGARDA® in NCCN Clinical Practice Guidelines for B-Cell Lymphomas

Invivyd, Inc. has announced that its investigational monoclonal antibody, PEMGARDA® (pemivibart), has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for ...

Study confirms it's 'never too late' to see survival benefits from quitting smoking—even with late-stage cancer

New research published online in the Journal of the National Comprehensive Cancer Network finds that people with cancer who ...
Business Insider

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute ...

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the ...
Medscape

The Virtues and Vices of the NCCN Guidelines

HOLLYWOOD, Florida ― Now in their 20th year, the National Comprehensive Cancer Network (NCCN) guidelines have greatly evolved from early efforts and continue to add new wrinkles, according to ...
Medscape

NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer

Medscape Hematology-Oncology is pleased to present the latest update to the NCCN Clinical Practice Guidelines in Oncology™ Prostate Cancer, released in December 2009. The updated NCCN Guideline, ...